PTL is a world-leading innovator in the fields of recombinant proteins, protein engineering, biotherapeutics, biosensors, and bioreactors, and assay development. PTL operates from state-of-the-art laboratories at Manchester Science Park in the United Kingdom.
CRO services by experts in
Diagnostic Assay Development
Recombinant protein production
Diagnostic assay development in accordance with UK SMIs
Projects around the UK
Evaluation, validation and verification of IVD methods for CE/UKCA registration
Delivering tailored development of molecular diagnostic tests for new medical platforms for the UK market.
We deliver the rapid progress of your biologic candidate into production. We achieve this with our extensive process development capabilities, which are robust, reproducible and scalable.
Our Protein Characterization Services portfolio offers access to a broad range of support facilities allowing for structural integrity analysis to check for protein folding, stability and aggregation of all expressed and purified molecules.
Protein Technologies Ltd. is a leader in the area of diagnostics and drug development for rare or neglected diseases. Currently the company is working to develop effective diagnostic tools and therapies for certain rare diseases.
Protein Technologies Ltd. (PTL) is an award-winning, biotech company established in 2010. The company provides contract research services to the biotech industry.
Since its conception it has received multiple awards and funding from the UK government’s Technology Strategy Board (now Innovate UK), Bill and Melinda Gates Foundation and The Wellcome Trust for its innovation in biotechnology.
PTL is a world-leading innovator in the fields of recombinant proteins, protein engineering, biotherapeutics, biosensors, and bioreactors. PTL operates from state-of-the-art laboratories at Manchester Science Park in the United Kingdom.
Protein Technologies Limited
(Laboratory No. 22691)
Medical laboratories - Requirements for quality and competence
BiOspace was founded within the Manchester Science Park from a partnership between Protein Technologies Limited and Manchester Science Partnership. Ninety percent of biotech and med-tech companies experience failure within the first three years of launch due to the high financial burn rates in R&D, overheads and personnel costs. It has been estimated that biotech start-ups, including early stage companies, spend over 50% of…
The project will examine protein aggregation biomarkers around this much mis-understood disease. This 12 month project is being Funded by the Manx MSA Trust who would like to make the Island a hub for better diagnosis of this illness. The project was initiated by Courtenay Heading of Jurby Wellness by calling on the Scientific expertise of: Protein Technologies headed by Dr Farid Khan and CynapseDX headed by Damian Bond. The collaboration team is…
Since the 1950s the use of chemical fertilisers has grown exponentially to cope with the increased consumption of food. The use of chemical fertilisers has led to environmental contamination, reduced biodiversity, disease prone plants, reduction of microbial organisms that support soil life, etc. Conversely, organic fertilizers improve soil structure, improve water retention, enhance soil fertility…
Get in touch